^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    GBP1 (Guanylate Binding Protein 1)

    i
    Other names: GBP1, Guanylate Binding Protein 1, Guanylate Binding Protein 1 Interferon-Inducible 67kDa, Interferon-Induced Guanylate-Binding Protein 1, Guanine Nucleotide-Binding Protein 1, Guanylate-Binding Protein 1, GTP-Binding Protein 1, HuGBP-1, GBP-1, Guanylate Binding Protein 1 Interferon-Inducible
    21d
    Combined therapy with the estrogen receptor ERα and IFNα-2b suppresses HBV replication by inducing GBP1 expression. (PubMed, Front Immunol)
    Interestingly, GBP1 was enriched in the NOD-like signalling pathway, which activates the host immune response.Our study demonstrated that the combination of ERα and peg IFNα-2b exerts antiviral effects by mediating the high expression of GBP1. These findings reveal the associations among ERα, peg IFNα-2b, and innate antiviral immunity, which target GBP1.
    Journal
    |
    ER (Estrogen receptor) • GBP1 (Guanylate Binding Protein 1) • IFNA1 (Interferon Alpha 1)
    2ms
    GBP1 as a machine learning-prioritized biomarker and therapeutic target for epstein-barr virus-induced clear cell renal cell carcinoma: multi-omics causal validation. (PubMed, Int J Surg)
    This work reveals a causal relationship between EBV infection and ccRCC pathogenesis, establishing GBP1 as a top-priority candidate molecule through a multi-level, multi-dimensional evidence framework. Drug prediction and molecular docking suggest finasteride as a potential inhibitor of GBP1, offering new strategies for the precise prevention and treatment of ccRCC.
    Journal
    |
    GBP5 (Guanylate Binding Protein 5) • GBP1 (Guanylate Binding Protein 1) • IFI16 (Interferon Gamma Inducible Protein 16) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) • RECQL (RecQ Like Helicase)
    |
    finasteride
    3ms
    Decoding Triphenotypic Neutrophils in Cervical Cancer Evolution and Targeting SPP1+/GBP1+/ELOVL5+ Tumor-Associated Neutrophils to Sensitize Immunotherapy. (PubMed, Adv Sci (Weinh))
    4) Finally, to explore the therapeutic value of TANs, we performed in vivo experiments, demonstrating that the combination of anti-Ly6G and anti-PD1 therapy resulted in improved anti-tumor efficacy compared with anti-PD1 monotherapy for CC. In conclusion, the study innovatively elucidated the three tissue-specific neutrophils stages in the progression of "normal-HSIL-CC", providing novel insights into TANs as potential targets for improving CC immunotherapeutic efficacy.
    Journal
    |
    SPP1 (Secreted Phosphoprotein 1) • GBP1 (Guanylate Binding Protein 1)
    4ms
    Breaking the heterogeneity barrier: a robust prognostic signature for survival stratification and immune profiling in triple-negative breast cancer. (PubMed, Front Immunol)
    This study established a transcriptomic heterogeneity-resilient prognostic model for TNBC, enabling precise survival stratification and immune microenvironment assessment. The integrative nomogram and risk-guided therapeutic predictions address clinical challenges in TNBC management, advancing personalized treatment strategies.
    Journal • IO biomarker
    |
    CYP4B1 (Cytochrome P450 Family 4 Subfamily B Member 1) • GBP1 (Guanylate Binding Protein 1)
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    5ms
    Polysaccharides isolated from Ganoderma bambusicola: Structural characterization and in vitro bioactivities. (PubMed, Int J Biol Macromol)
    Among the three polysaccharides, GBP-3 exhibited the most potent antitumor activity, reducing cell viability by 75 % at 400 μg/mL, compared to 45 % for both GBP-1 and GBP-2. These findings highlight the potential of G. bambusicola polysaccharides in cancer therapy, possibly through modulation of the tumor micro-environment.
    Preclinical • Journal
    |
    GBP1 (Guanylate Binding Protein 1)
    5ms
    A STAT1-GBP1 axis modulates epithelial proliferation in postpartum breast tissue by repressing CDKI expression. (PubMed, Breast Cancer Res)
    These findings identify a STAT1-GBP1 axis that enhances postpartum epithelial proliferation by repressing CDKI expression. This mechanism may help to explain the heightened vulnerability observed after childbirth and highlights potential biomarkers or early intervention targets in postpartum breast tissues.
    Journal
    |
    STAT1 (Signal Transducer And Activator Of Transcription 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • GBP1 (Guanylate Binding Protein 1) • CDKN1C (Cyclin Dependent Kinase Inhibitor 1C)
    5ms
    GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape. (PubMed, Neoplasia)
    Specifically, our results reveal that GBP1 regulates PD-L1 expression by activating CDK9 and promoting STAT3 phosphorylation. These findings suggest that targeting GBP1 may represent a promising therapeutic strategy for the treatment of osteosarcoma by impairing tumor immune evasion.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CDK9 (Cyclin Dependent Kinase 9) • GBP1 (Guanylate Binding Protein 1)
    |
    PD-L1 expression
    5ms
    Protein-based classification reveals an immune-hot subtype in IDH mutant astrocytoma with worse prognosis. (PubMed, Cancer Cell)
    Finally, we develop an AI-powered classifier for patient stratification. Our work delineates protein-based clustering of IDH-mutant astrocytoma and reveals an immune-hot subgroup that may inform therapeutic development.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • GBP1 (Guanylate Binding Protein 1)
    |
    CDKN2A deletion
    7ms
    A randomized, open-label, multicenter clinical study comparing the combination of epalorlimovalizumab and bevacizumab with TAS-102 versus bevacizumab combined with TAS-102 in the second-line treatment of advanced colorectal cancer (ChiCTR2500106797)
    P4, N=84, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New P4 trial
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • GBP5 (Guanylate Binding Protein 5) • STAT1 (Signal Transducer And Activator Of Transcription 1) • APOE (Apolipoprotein E) • GBP1 (Guanylate Binding Protein 1) • TAP1 (Transporter 1) • GBP4 (Guanylate Binding Protein 4) • MX1 (MX Dynamin Like GTPase 1) • SDC2 (Syndecan 2)
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8ms
    Multifaceted Roles of Guanylate-Binding Proteins in Cancer. (PubMed, Int J Mol Sci)
    This comprehensive review explores the structural intricacies, immune functions, and multifaceted contributions of human GBPs to cancer, delving into their molecular mechanisms, prognostic potential, and therapeutic implications. We incorporate the latest insights to highlight how understanding GBP regulation could reshape cancer treatment strategies.
    Review • Journal
    |
    GBP1 (Guanylate Binding Protein 1)
    8ms
    A prognostic gene signature and subtype-specific drug sensitivity in TNBC revealed by single-cell and bulk RNA sequencing: Insights into stemness and tumor heterogeneity. (PubMed, Methods)
    This signature robustly stratified patients by overall survival across both internal and external cohorts. Overall, our findings provide critical insights into the molecular drivers of chemoresistance in TNBC and offer a foundation for personalized therapeutic strategies.
    Journal • Gene Signature • BRCA Biomarker
    |
    BCL2A1 (BCL2 Related Protein A1) • GBP1 (Guanylate Binding Protein 1)
    10ms
    Transcriptome insights into newcastle disease virus-mediated eradication of cholangiocarcinoma cells. (PubMed, PLoS One)
    In addition, gene network analysis highlighted CCNA2, CDK1, DDX58, DHX58, EXO1, GBP1, IFIH1, IFIT1, IFIT2, IFIT3, IRF7, ISIG15, MX1, OAS1, OAS2, PARP9, TOP2A and XAF1 as potential hub genes influencing the response of CCA cells to NDV LaSota strain. Our findings offer evidence supporting the promise of NDV-based therapies as potential strategies for eliminating CCA cells.
    Journal • PARP Biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • TOP2A (DNA topoisomerase 2-alpha) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TGM2 (Transglutaminase 2) • CCNA2 (Cyclin A2) • IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • CDK1 (Cyclin-dependent kinase 1) • GBP1 (Guanylate Binding Protein 1) • IFIH1 (Interferon Induced With Helicase C Domain 1) • DDX58 (DExD/H-Box Helicase 58) • IFIT2 (Interferon Induced Protein With Tetratricopeptide Repeats 2) • IRF7 (Interferon Regulatory Factor 7) • MX1 (MX Dynamin Like GTPase 1) • XAF1 (XIAP Associated Factor 1)